Third Harmonic Bio stockholders approve liquidation plan, set distribution

Published 12/06/2025, 13:06
Third Harmonic Bio stockholders approve liquidation plan, set distribution

SAN FRANCISCO - Third Harmonic Bio, Inc. (NASDAQ:THRD), a biotech company with a market capitalization of $237.37 million and notably strong liquidity position, has received stockholder approval for its Plan of Liquidation and Dissolution with 99.9% of votes cast in favor at the Annual Meeting held on June 5, according to a press release statement. InvestingPro data shows the company maintains more cash than debt on its balance sheet, with a robust current ratio of 54.1.

The company expects to make an initial distribution to stockholders in the third quarter of 2025, estimated between $5.30 and $5.35 per share of common stock. Total distributions are projected to range between approximately $5.30 and $5.44 per share. This comes as the stock has experienced significant volatility, with InvestingPro data showing a 53% decline over the past six months, though the current trading price of $5.26 suggests the market is closely aligned with the expected distribution value.

The biotech firm also reported results from an additional cohort in its Phase 1 clinical trial of THB335, an oral wild-type KIT inhibitor. The 100mg once-daily dose using a new capsule formulation demonstrated an 85% mean reduction in serum tryptase, a biomarker of mast cell activation. All adverse events were mild, except for one moderate case of neutrophil reduction.

Third Harmonic Bio has completed clinical, toxicology and manufacturing activities to support a Phase 2 clinical trial of THB335 for chronic spontaneous urticaria. The company plans to submit a regulatory filing to the FDA for trial clearance.

As part of its dissolution plan, the company is initiating a sale process for THB335 and related intellectual property. The final distribution amount may vary based on several factors, including potential proceeds from asset sales.

The liquidation plan received approval from 83.7% of the company’s total outstanding common shares.

In other recent news, Third Harmonic Bio announced a significant development with its board of directors approving a Plan of Liquidation and Dissolution. This plan, pending stockholder approval at the upcoming annual meeting, is set to distribute between $246.6 million and $259.8 million to shareholders, equating to approximately $5.13 to $5.42 per share. The company aims to sell its assets, including the THB335 program, to maximize shareholder value. Meanwhile, Stifel has downgraded Third Harmonic Bio’s stock from Buy to Hold, reducing the price target significantly from $23.00 to $5.00, citing uncertainties in the development of THB335 despite promising Phase 1 data. Raymond James maintained a Market Perform rating on the stock following the liquidation announcement. Additionally, Third Harmonic Bio disclosed the departure of its Chief Scientific Officer, Christopher Dinsmore, who has entered a separation agreement with the company. The company is yet to name a successor for this position. These recent developments highlight a period of transition and strategic reevaluation for Third Harmonic Bio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.